×
About 62,936 results

ALLMedicine™ Pancreatic Cancer Center

Research & Reviews  29,735 results

Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion.
https://doi.org/10.1186/s12885-020-07697-1
BMC Cancer; Tekin C, Aberson HL et. al.

Dec 3rd, 2020 - Pancreatic ductal adenocarcinoma (PDAC) is a grim disease with high mortality rates. Increased macrophage influx in PDAC is a common hallmark and associated with poor prognosis. Macrophages have high cellular plasticity, which can differentiate in...

Relationship between surgical R0 resectability and findings of peripancreatic vascular ...
https://doi.org/10.1186/s12885-020-07698-0
BMC Cancer; Yasuta S, Kobayashi T et. al.

Dec 3rd, 2020 - Borderline resectable pancreatic cancer (BRPC) is frequently associated with positive surgical margins and a poor prognosis because the tumor is in contact with major vessels. This study evaluated the relationship between the margin-negative (R0) ...

Effect of bacterial contamination in bile on pancreatic cancer cell survival.
https://doi.org/10.1016/j.surg.2020.09.029
Surgery Shrader HR, Miller AM et. al.

Dec 3rd, 2020 - Introduction of gut flora into the biliary system is common owing to biliary stenting in patients with obstructing pancreatic head cancer. We hypothesize that alteration of biliary microbiome modifies bile content that modulates pancreatic cancer ce...

Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 prot...
https://doi.org/10.1158/1535-7163.MCT-20-0365
Molecular Cancer Therapeutics; Parsels LA, Engelke CG et. al.

Dec 3rd, 2020 - PARP inhibitor monotherapy (olaparib) was recently FDA-approved for the treatment of BRCA1/2 mutant, HR (homologous recombination repair)-deficient pancreatic cancer. Most pancreatic cancers, however, are HR-proficient and thus resistant to PARP i...

Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort...
https://doi.org/10.1007/s11605-020-04870-6
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract; Kaltenmeier C, Nassour I et. al.

Dec 3rd, 2020 - To assess the predictors and influence of resection margins and the role of neoadjuvant and adjuvant therapy on survival for a national cohort of patients with resected pancreatic cancer. Using the National Cancer Data Base between 2004 and 2016, ...

see more →

Guidelines  87 results

Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practic...
https://doi.org/10.1016/j.prro.2019.06.016
Practical Radiation Oncology; Palta M, Godfrey D et. al.

Sep 2nd, 2019 - This guideline systematically reviews the evidence for treatment of pancreatic cancer with radiation in the adjuvant, neoadjuvant, definitive, and palliative settings and provides recommendations on indications and technical considerations. The Am...

Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recomm...
https://doi.org/10.1001/jama.2019.10232
JAMA , Owens DK et. al.

Aug 6th, 2019 - Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its ...

Screening for Pancreatic Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2740726
JAMA

Aug 5th, 2019 - Importance Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States. Objective To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Prev...

Screening for Pancreatic Cancer US Preventive Services Task Force Reaffirmation Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2740727
JAMA

Aug 4th, 2019 - Importance Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. A...

see more →

Drugs  89 results see all →

Clinicaltrials.gov  31,617 results

Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion.
https://doi.org/10.1186/s12885-020-07697-1
BMC Cancer; Tekin C, Aberson HL et. al.

Dec 3rd, 2020 - Pancreatic ductal adenocarcinoma (PDAC) is a grim disease with high mortality rates. Increased macrophage influx in PDAC is a common hallmark and associated with poor prognosis. Macrophages have high cellular plasticity, which can differentiate in...

Relationship between surgical R0 resectability and findings of peripancreatic vascular ...
https://doi.org/10.1186/s12885-020-07698-0
BMC Cancer; Yasuta S, Kobayashi T et. al.

Dec 3rd, 2020 - Borderline resectable pancreatic cancer (BRPC) is frequently associated with positive surgical margins and a poor prognosis because the tumor is in contact with major vessels. This study evaluated the relationship between the margin-negative (R0) ...

Effect of bacterial contamination in bile on pancreatic cancer cell survival.
https://doi.org/10.1016/j.surg.2020.09.029
Surgery Shrader HR, Miller AM et. al.

Dec 3rd, 2020 - Introduction of gut flora into the biliary system is common owing to biliary stenting in patients with obstructing pancreatic head cancer. We hypothesize that alteration of biliary microbiome modifies bile content that modulates pancreatic cancer ce...

Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 prot...
https://doi.org/10.1158/1535-7163.MCT-20-0365
Molecular Cancer Therapeutics; Parsels LA, Engelke CG et. al.

Dec 3rd, 2020 - PARP inhibitor monotherapy (olaparib) was recently FDA-approved for the treatment of BRCA1/2 mutant, HR (homologous recombination repair)-deficient pancreatic cancer. Most pancreatic cancers, however, are HR-proficient and thus resistant to PARP i...

Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort...
https://doi.org/10.1007/s11605-020-04870-6
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract; Kaltenmeier C, Nassour I et. al.

Dec 3rd, 2020 - To assess the predictors and influence of resection margins and the role of neoadjuvant and adjuvant therapy on survival for a national cohort of patients with resected pancreatic cancer. Using the National Cancer Data Base between 2004 and 2016, ...

see more →

News  1,319 results

Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed 
https://www.staging.medscape.com/viewarticle/941278

Nov 18th, 2020 - The PARP inhibitor olaparib (Lynparza) has been shown to delay progression  in patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations, and is now approved for this indication. A new study suggests that this approach can be cost-e...

Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed 
https://www.medscape.com/viewarticle/941278

Nov 18th, 2020 - The PARP inhibitor olaparib (Lynparza) has been shown to delay progression  in patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations, and is now approved for this indication. A new study suggests that this approach can be cost-e...

Alex Trebek Dies After Battle With Pancreatic Cancer
https://www.medscape.com/viewarticle/940613

Nov 8th, 2020 - Alex Trebek, the long-running host of the game show Jeopardy! whose sharp wit, dry humor, and celebration of the intellect made him one of television's most beloved icons, has died. The cause was pancreatic cancer, according to a statement from th...

Digoxin Use Linked to Pancreatic Cancer Risk, But Does Not Affect Overall Survival
https://www.staging.medscape.com/viewarticle/940259

Nov 4th, 2020 - Takeaway Digoxin use was associated with an increased risk of developing pancreatic cancer. However, no association was seen between digoxin use and overall survival. Why this matters Physicians should consider initiating digoxin therapy in patien...

Digoxin Use Linked to Pancreatic Cancer Risk, But Does Not Affect Overall Survival
https://www.medscape.com/viewarticle/940259

Nov 4th, 2020 - Takeaway Digoxin use was associated with an increased risk of developing pancreatic cancer. However, no association was seen between digoxin use and overall survival. Why this matters Physicians should consider initiating digoxin therapy in patien...

see more →

Patient Education  89 results see all →